Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$453M |
| 2 |
CELG
Celgene Corp
CELG
|
+$391M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$389M |
| 4 |
GE Aerospace
GE
|
+$378M |
| 5 |
Johnson & Johnson
JNJ
|
+$356M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$307M |
| 2 |
Costco
COST
|
+$279M |
| 3 |
Lowe's Companies
LOW
|
+$273M |
| 4 |
Microsoft
MSFT
|
+$230M |
| 5 |
Chevron
CVX
|
+$225M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.59% |
| 2 | Technology | 14.11% |
| 3 | Financials | 10.92% |
| 4 | Consumer Discretionary | 9.85% |
| 5 | Real Estate | 7.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ALEX
2901
DELISTED
Alexander & Baldwin
ALEX
| $636K | ﹤0.01% |
+27,531
| New | +$653K |
|
|
AINC
2902
DELISTED
Ashford Inc.
AINC
| $635K | ﹤0.01% |
19,980
+5,900
| +42% | +$282K |
|
|
SGMA
2903
DELISTED
Sigmatron International
SGMA
| $633K | ﹤0.01% |
243,529
-8,617
| -3% | -$22.7K |
|
|
DOG
2904
ProShares Short Dow30
DOG
$112M
| $631K | ﹤0.01% |
+11,800
| New | +$645K |
|
2905
Inovio Pharmaceuticals
INO
$85.6M
| $631K | ﹤0.01% |
17,890
-29,133
| -62% | -$1.16M |
|
|
SDI
2906
DELISTED
Standard Diversified Inc. Class A Common Stock
SDI
| $630K | ﹤0.01% |
33,005
-1,100
| -3% | -$21.4K |
|
2907
iShares S&P 500 Growth ETF
IVW
$70.5B
| $627K | ﹤0.01% |
+14,000
| New | +$616K |
|
2908
Cardiff Oncology
CRDF
$63M
| $623K | ﹤0.01% |
249,121
+88,900
| +55% | +$285K |
|
2909
SCYNEXIS
SCYX
$37.4M
| $623K | ﹤0.01% |
5,941
+2,748
| +86% | +$317K |
|
|
FSB
2910
DELISTED
Franklin Financial Network, Inc.
FSB
| $621K | ﹤0.01% |
+22,300
| New | +$620K |
|
2911
Achieve Life Sciences
ACHV
$633M
| $620K | ﹤0.01% |
16,063
+1,780
| +12% | +$126K |
|
2912
KBR
KBR
$4.56B
| $619K | ﹤0.01% |
24,800
-113,200
| -82% | -$2.53M |
|
|
TOO
2913
DELISTED
Teekay Offshore Partners L.P.
TOO
| $614K | ﹤0.01% |
487,318
+243,718
| +100% | +$308K |
|
2914
iShares Agency Bond ETF
AGZ
$559M
| $611K | ﹤0.01% |
5,300
-5,800
| -52% | -$660K |
|
2915
Woodward
WWD
$23B
| $611K | ﹤0.01% |
5,400
-6,484
| -55% | -$695K |
|
2916
Vanguard Mega Cap Growth ETF
MGK
$31.3B
| $609K | ﹤0.01% |
+23,500
| New | +$598K |
|
|
ERF
2917
DELISTED
Enerplus Corporation
ERF
| $607K | ﹤0.01% |
80,657
-374,718
| -82% | -$3.07M |
|
2918
Tredegar Corp
TG
$260M
| $602K | ﹤0.01% |
36,200
-48,400
| -57% | -$818K |
|
|
JASN
2919
DELISTED
Jason Industries, Inc.
JASN
| $601K | ﹤0.01% |
924,671
-16,600
| -2% | -$19.6K |
|
2920
ImmuCell
ICCC
$99.6M
| $598K | ﹤0.01% |
92,006
+700
| +0.8% | +$4.44K |
|
|
BGMS
2921
Bio Green Med Solution Inc
BGMS
$4.86M
| $596K | ﹤0.01% |
15
+7
| +88% | +$339K |
|
2922
First Guaranty Bancshares
FGBI
$155M
| $595K | ﹤0.01% |
34,546
+6,341
| +22% | +$111K |
|
2923
iShares S&P India Nifty 50 Index Fund
INDY
$558M
| $595K | ﹤0.01% |
+15,500
| New | +$590K |
|
2924
Indaptus Therapeutics
INDP
$243M
| $593K | ﹤0.01% |
+61
| New | +$769K |
|
|
VSLR
2925
DELISTED
VIVINT SOLAR, INC.
VSLR
| $593K | ﹤0.01% |
+81,230
| New | +$513K |
|
Similar funds
Renaissance Technologies's Q2 2019 Portfolio in Review
As of Q2 2019, Renaissance Technologies held 3,913 positions worth $114B, up 3.3% from $110B the previous quarter. Its ten largest holdings account for 9.1% of the portfolio.
Renaissance Technologies's Q2 2019 filing shows 495 new, 1,847 increased, 1,145 reduced and 397 closed positions. Its largest new stake was Apple: 9,290,160 shares worth $460M. The largest sale was UnitedHealth, an estimated $307M.
By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 16% a quarter earlier, followed by Technology and Financials.
- Renaissance Technologies's largest Q2 2019 buy was Apple: 9,290,160 shares worth $460M.
- Renaissance Technologies added most to Celgene Corp in Q2 2019, an estimated $391M increase.
- Renaissance Technologies's biggest Q2 2019 reduction was Microsoft, cutting an estimated $230M.
- Renaissance Technologies fully exited UnitedHealth in Q2 2019, selling an estimated $307M.
- Renaissance Technologies's ten largest holdings make up 9.1% of its $114B portfolio in Q2 2019.
- Renaissance Technologies opened 495 new positions and closed 397 in Q2 2019.
- Renaissance Technologies's portfolio value rose 3.3% quarter-over-quarter to $114B.
Based on Renaissance Technologies's 13F filing for Q2 2019, filed 12 Aug 2019.